Akebia Therapeutics
AKBA
169 hedge funds and large institutions have $695M invested in Akebia Therapeutics in 2019 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 48 increasing their positions, 51 reducing their positions, and 25 closing their positions.
112% more call options, than puts
Call options by funds: $3.23M | Put options by funds: $1.52M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
55% more capital invested
Capital invested by funds: $448M → $695M (+$246M)
16% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 25
2.51% more ownership
Funds ownership: 69.91% → 72.42% (+2.5%)
2% more funds holding
Funds holding: 166 → 169 (+3)
6% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$9.82M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$7.83M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.15M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.11M |
| 5 |
TA
Teachers Advisors
New York
|
+$4.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$9.66M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.46M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$3.41M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$3.2M |
| 5 |
Citigroup
New York
|
-$1.77M |
AKBA Hedge Fund Activity: Q1 2019 in Review
169 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2019, worth a combined $695M — up 55% from $448M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AKBA positions and 25 closed out — a net gain of 4 holders — while 48 added to existing stakes and 51 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $9.82M. The largest seller was Citadel Advisors, cutting an estimated $9.66M.
- 169 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2019, up from 166 in Q4 2018.
- Funds reported $695M of Akebia Therapeutics stock for Q1 2019, up 55% quarter-over-quarter.
- 29 funds opened new Akebia Therapeutics positions in Q1 2019 and 25 closed out, a net change of +4 holders.
- The largest Akebia Therapeutics buyer in Q1 2019 was Consonance Capital Management, an estimated $9.82M added.
- The largest Akebia Therapeutics seller in Q1 2019 was Citadel Advisors, an estimated $9.66M sold.
Based on aggregated 13F filings for Q1 2019.